Covid-19, Ema has approved updated vaccines

Covid-19, Ema has approved updated vaccines
Covid-19, Ema has approved updated vaccines
CopyAMP code

The Committee for Medicinal Products for Human Use of the European Medicines Agency (Ema) has recommended theauthorization of two bivalent vaccines against Covid-19, updated to provide a wider protection against Sars-cov-2 variants. Ema herself announces it in a note. The new vaccines, adapted versions of those in mRna Comirnaty (produced by Pfizer / BioNTech) and Spikevax (produced by Moderna) capable of affecting, in addition to the original strain, also the omicron variant of the coronavirus, are destined to be given to people aged 12 years or older who have completed at least the primary vaccination against Covid-19. The opinion of the EMA has been sent to the European Commission, which will take a final decision on the matter.

Keeping the evolution of the pandemic under control

As the Covid-19 pandemic evolves, increases also there diffusion of variants of Sars-cov-2: in particular, starting from the beginning of 2022, omicron and the sub-variants associated with this lineage (such as, for example, omicron 2 and omicron 5) began to spread rapidly, ousting the other circulating coronavirus variants. This has led health authorities to seek strategies to continue to combat the pandemic: among these, the adoption of vaccines updated, able to broaden the immune response against different variants of Sars-cov-2 and which should therefore help maintain optimal protection against Covid-19 as the virus evolves and continues to spread.

Among the new vaccines developed by biotech companies there are also Comirnaty Original / Omicron Ba.1 and Spikevax Bivalent Original / Omicron Ba.1, two mRna vaccines produced by Pfizer / BionTech and Moderna respectively, directed against both the original strain and the omicron variant of Sars-cov-2. This is the updated version of Comirnaty and Spikevax, mRna vaccines, among the protagonists of the past vaccination campaigns against Covid-19. Bivalent vaccines work with the same mechanism as their predecessors: they, in fact, contain molecules of mRna that have the instructions for produce spike proteins both belonging to the original Sars-cov-2 strain and to the omicron variantwhich in fact has several mutations in the protein itself.

When a person receives the updated vaccine, the latter it will teach your immune system to reactshould he come into contact with you, both against spikes of Sars-cov-2 original and of the omicron variant. In this way, administering such a vaccine should guarantee wider protection than primary vaccination (which included, we recall, the administration of vaccines directed against spikes of the original Sars-cov-2).


Studies in favor and the future of vaccines

CopyAMP code

Ema’s opinion, that recommends the authorization of both updated vaccines to persons 12 years of age and older at least three months after completion of the primary vaccination or administration of the booster dose, is based on several studies that have tested its safety and efficacy. In particular, the studies (which altogether involved more than 3200 people) have shown that the two vaccines are bivalent they are able to trigger strong immune responses against omicron and native Sars-cov-2 in people previously vaccinated (even in those with a booster dose).

The article is in Italian

Tags: Covid19 Ema approved updated vaccines

PREV How the health system has changed after Covid, the analysis entrusted to a Civic doctor
NEXT 17,668 new cases and 48 deaths –